The word microdosing appears in two unrelated bodies of literature. In pharmacology research, it refers to a specific regulatory category — sub-pharmacological doses (typically ≤100 micrograms) administered in early-phase clinical trials to study how a compound is absorbed and metabolized. In contemporary public usage, the term refers to something entirely different: the practice, described in popular literature beginning around 2011, of taking small quantities of psychedelic substances on a structured schedule. The two usages share a name but have separate origins, separate definitions, and separate research literatures. Recognizing which meaning a given source is using is the first step in reading research on either topic accurately.
Why this matters
If you are reading research on either topic and do not know which definition is in play, you can easily draw conclusions the underlying study does not support. The two literatures use different methodologies, study different dose ranges, and answer different questions. A pharmacology paper about a Phase 0 microdose trial and a behavioural-science paper about self-reported microdosing have almost nothing in common except the word in their titles. This article walks through both meanings, how they came about, and how to tell them apart when reading published research. A shorter version of the same disambiguation appears in the 90-second summary on iMicrodosing.net.
- 2003 EMA Position Paper
European Medicines Agency publishes position paper outlining single-microdose studies.
- 2006 FDA Guidance
U.S. Food and Drug Administration codifies exploratory IND framework, including microdose category.
- 2009 ICH M3(R2)
International Council for Harmonisation publishes harmonized guidance covering microdose criteria across jurisdictions.
- 2024 Continued use
Phase 0 microdose studies remain an active drug-development methodology, reviewed in current pharmacology literature.
- 2011 Fadiman publication
”The Psychedelic Explorer’s Guide” dedicates a chapter to the topic, introducing a structured schedule now widely referenced.
- 2015 Popular awareness rises
Coverage in popular and trade media expands following Fadiman’s public discussion of the practice.
- 2019 First systematic studies
Polito & Stevenson publish first systematic observational study; Kuypers et al. publish first major peer-reviewed review of the field.
- 2024 Emerging research base
Observational and controlled studies continue to accumulate, though the literature remains methodologically distinct from regulatory pharmacology.
- Pharmacological microdose
- A regulatory definition: less than 1/100th of the calculated pharmacologically active dose, capped at 100 micrograms. [1] Government Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies Link →
- Phase 0 trial
- An exploratory clinical study used to gather early pharmacokinetic data using microdoses, conducted before traditional Phase 1 safety studies. [2] Peer-reviewed The application of Phase 0 and microtracer approaches in early clinical development: past, present, and future doi:10.3389/fphar.2024.1369079
- Sub-perceptual usage
- A separate, non-regulatory usage of the term, popularized in 2011 literature, referring to amounts of psychedelic substances reported as below the threshold of noticeable effects. [3] Practitioner The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys Link →
- Definitional ambiguity
- A documented feature of the current research landscape: academic pharmacology and public discussion often use the same word for non-overlapping concepts. [4] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204
Two terms, one word
The word microdosing now appears across academic journals, regulatory documents, popular media, and everyday conversation. In each setting, it can refer to different things. Recognizing the difference is foundational to reading published research carefully.
In pharmacology, the term acquired a defined regulatory meaning during the early 2000s. Authorities including the European Medicines Agency and the U.S. Food and Drug Administration introduced “microdose studies” as a category of exploratory clinical investigation. [5] Government Position Paper on Non-Clinical Safety Studies to Support Clinical Trials with a Single Microdose (CPMP/SWP/2599/02) Link → [1] Government Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies Link → A peer-reviewed 2019 review in the Journal of Psychopharmacology explicitly noted that pharmacology and contemporary popular discussion use the same term for unrelated practices. [4] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204
In public usage, the term refers to something else entirely. Its appearance in popular discourse is generally traced to a 2011 book by psychologist James Fadiman, who devoted a chapter to the concept and provided a structured schedule that has since become widely referenced. [3] Practitioner The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys Link → The public meaning continues to evolve and is not bound by the regulatory definitions used in pharmacology.
This article examines both usages and the implications of the overlap for readers of research literature.
The pharmacological definition
The pharmacological meaning of microdosing developed from regulatory and methodological work during the early 2000s. The European Medicines Agency published a position paper in 2003 outlining the conditions under which a “single microdose” study could proceed with reduced preclinical safety data. [5] Government Position Paper on Non-Clinical Safety Studies to Support Clinical Trials with a Single Microdose (CPMP/SWP/2599/02) Link → The U.S. Food and Drug Administration issued parallel guidance in 2006 codifying the same general framework for exploratory studies in humans. [1] Government Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies Link →
Within both frameworks, a microdose is defined by two thresholds. The dose must be less than one one-hundredth of the dose calculated, based on animal data, to produce a pharmacological effect in humans. Separately, the total dose generally must not exceed 100 micrograms, with a lower threshold of 30 nanomoles applying to protein products. [2] Peer-reviewed The application of Phase 0 and microtracer approaches in early clinical development: past, present, and future doi:10.3389/fphar.2024.1369079 The boundary is intended to ensure that a microdose remains below the threshold of pharmacological activity while still being detectable through sensitive analytical methods such as accelerator mass spectrometry.
Phase 0 studies
Microdose investigations typically appear in what regulators describe as Phase 0 trials. These are exploratory studies conducted before the traditional Phase 1 dose-escalation studies that begin a clinical development program. [1] Government Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies Link → A 2024 review in Frontiers in Pharmacology described their purpose as the early collection of pharmacokinetic data — how a compound is absorbed, distributed, metabolized, and eliminated — using extremely small quantities and short observation windows. [2] Peer-reviewed The application of Phase 0 and microtracer approaches in early clinical development: past, present, and future doi:10.3389/fphar.2024.1369079
Because a microdose is, by definition, sub-pharmacological, Phase 0 studies generally require less preclinical safety data than larger trials. This can reduce time and the use of animal testing during early candidate evaluation. The 2024 review notes that the original rationale for the framework was to allow drug developers to gather preliminary human data on candidate compounds without committing to the full preclinical package typically required for Phase 1 studies. [2] Peer-reviewed The application of Phase 0 and microtracer approaches in early clinical development: past, present, and future doi:10.3389/fphar.2024.1369079
Microdosing in popular usage
The use of microdosing in popular literature developed independently of the regulatory pharmacology meaning. The 2019 review in the Journal of Psychopharmacology describes it as a phenomenon that “has seen a rapid explosion of popularity in recent years,” distinct from the regulatory definition that predates it by roughly a decade. [4] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204
In this usage, the term refers to the regular ingestion of small quantities of psychedelic substances on a structured schedule, characterized in popular literature as remaining below the threshold of noticeable acute effects. The first widely cited written description is generally attributed to Fadiman’s 2011 book, which devoted a chapter to the topic and introduced a structured schedule now commonly referenced in popular discussion. [3] Practitioner The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys Link →
The published research base examining this practice is younger and methodologically different from the pharmacology literature on Phase 0 trials. The Polito and Stevenson 2019 study in PLoS ONE — among the first systematic empirical investigations of self-reported microdosing — tracked daily reports from 98 participants over a six-week period. [6] Peer-reviewed A systematic study of microdosing psychedelics doi:10.1371/journal.pone.0211023 Its design was observational rather than controlled, and the authors explicitly noted that the legal and bureaucratic context makes direct empirical investigation difficult. [6] Peer-reviewed A systematic study of microdosing psychedelics doi:10.1371/journal.pone.0211023
How the two definitions compare
The two usages share a word and very little else. They differ in their origins, their dose categories, their study designs, and the literatures they inhabit.
| Attribute | Pharmacological microdose | Public usage of the term |
|---|---|---|
| Defined by | FDA / EMA / ICH regulatory guidance | Popular literature, beginning ~2011 |
| First codified | 2003–2006 (regulatory) | 2011 (Fadiman) |
| Dose threshold | ≤ 1/100th of pharmacologically active dose; ≤ 100 µg | No formal definition; described in popular sources |
| Study context | Phase 0 / exploratory clinical trials | Observational and survey research |
| Primary literature | Pharmacology, clinical pharmacology | Psychopharmacology, behavioural science |
| Regulatory framework | FDA Guidance 2006; ICH M3(R2) | None — usage is descriptive |
The 2019 review in the Journal of Psychopharmacology explicitly contrasts the two: in pharmacology, the term describes “a process used in drug development… where a minute dose of a substance is used to assess the pharmacokinetics of a drug.” [4] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204 The popular usage refers to something separate, with its own emerging literature.
Why the distinction matters for reading research
For readers of published research, the practical implication is straightforward: identifying which definition a given source is using is a precondition for interpreting the source accurately.
A pharmacology paper describing a “microdose study” of a candidate compound is reporting on a regulatory Phase 0 trial. The methodology will reflect the FDA, EMA, or ICH framework. The dose will be in micrograms. The observation window will be short. The endpoints will be pharmacokinetic.
A behavioural science paper using the word microdosing is describing the popular-usage practice. The methodology will typically be observational or survey-based. The dose will be reported in larger quantities. The observation window will extend over weeks or months. The endpoints will be self-reported psychological measures.
The two literatures do not share methods, do not share samples, and generally do not cite one another. A reader who conflates them will draw incorrect inferences about either body of work. The 2019 review notes that this terminological overlap is a recognized source of confusion in the field and recommends that authors clarify which usage they intend when introducing the term. [4] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204
A note on terminology elsewhere in this library
For consistency, content elsewhere in this library uses microdosing in its popular-usage sense unless explicitly framed as pharmacological or regulatory context. Where pharmacological-microdose research is referenced, the term Phase 0 microdose or regulatory microdose is used to disambiguate. Readers consulting primary research should verify which definition applies to each source.
Frequently asked questions
Is the pharmacological definition of microdosing related to psilocybin or psychedelics?
No. The regulatory definition was developed for general drug development and applies to any compound studied in Phase 0 trials. It is not specific to psychedelics or to any particular drug category. The popular usage developed separately and is more commonly applied to psychedelic substances. [4] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204
When did the term first appear in academic literature?
The pharmacological meaning was formally codified through regulatory guidance documents published in 2003 (EMA) and 2006 (FDA), though related methodological discussions appeared in academic pharmacology earlier. [5] Government Position Paper on Non-Clinical Safety Studies to Support Clinical Trials with a Single Microdose (CPMP/SWP/2599/02) Link → [1] Government Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies Link → The popular usage is generally traced to a 2011 book by psychologist James Fadiman. [3] Practitioner The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys Link →
Why does the same word refer to two different things?
The two usages developed independently in different research and writing communities and arrived at the same word. Peer-reviewed reviews of the field have acknowledged this terminological overlap as an existing feature of the literature. [4] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204
How can I tell which meaning a source is using?
Look at where the source is published, what methodology it describes, and what doses or units it reports. Pharmacology and pharmacokinetics papers use the regulatory meaning; psychopharmacology and behavioural studies typically use the popular meaning. When uncertain, check whether the source references the FDA or EMA microdose framework, which signals the pharmacological usage.
Are there other terms for the popular usage?
Yes. Some literature uses sub-perceptual dosing, sub-threshold dosing, or low-dose psychedelic use to disambiguate from the regulatory definition. [6] Peer-reviewed A systematic study of microdosing psychedelics doi:10.1371/journal.pone.0211023 These terms are not yet standardized across the field.
In summary
Two unrelated definitions of microdosing now coexist in published literature. The first is a regulatory pharmacology category dating from the early 2000s, referring to sub-pharmacological doses (≤100 µg) used in exploratory Phase 0 clinical trials. The second is a separate popular usage introduced around 2011, referring to a self-reported practice involving small quantities of psychedelic substances on a structured schedule. The two share a word, predate one another in different decades, and inhabit separate research literatures with different methodologies. Recognizing which definition applies in any given source is the first step in reading microdosing research accurately.